Valeant will pay about $1 billion to buy Sprout Pharmaceuticals, the maker of the first prescription drug intended to boost sexual desire in women.
Teva agrees to buy Allergan's generic pharmaceuticals business for $40.5 billion in what analysts say is the largest-ever acquisition by an Israeli company.
CVS Health will buy Target's pharmacy and clinic businesses in a deal that combines resources of two retailers seeking to boost their health care images.
Plenty of stocks go up and down in any given week. These were some of the biggest gainers and decliners on Wall Street last week.
The Dow and S&P 500 ended a volatile session higher Tuesday, helped by strong earnings from Merck and gains in IBM, while the Nasdaq fell with Apple.
Spending on prescription drugs soared last year, driven up in part by a surge from millions of people newly insured under the Affordable Care Act.
Drug mater Mylan rises after it agrees to buy rival Perrigo, and Ocular Therapeutix falls after disappointing results for inflammation and pain treatment.
Stocks ended a volatile session up slightly Wednesday after minutes from a March meeting indicated that the Fed remained on track for a rate hike this year.
U.S. stocks climbed more than 1 percent Monday, rebounding from a sharp decline last week, helped by deal activity, especially in the health care sector.
Prescription drugs spending jumped 13 percent last year, the biggest annual increase since 2003, the nation's largest pharmacy benefits manager says.
The week's biggest winner was Eagle Pharmaceuticals, for a promising cancer drug, and the biggest loser was the fast-casual chain Noodles & Co.
The S&P 500 ended above 2,100 at another record high Tuesday as optimism grew that a debt deal would be reached with Greece and as bond prices sold off.
Legal use ushered in bipartisan politics, a reduction in crime, the rise of recreational over medicinal supply and a stunning defeat in Florida.
Actavis is paying $66 billion to buy fellow drugmaker Allergan in a deal that could finally end a months-long takeover battle for the Botox-maker.
Drug-giant Merck & Co. reports lower than expected third quarter revenue, but cost cuts enable the company to beat earnings forecasts.
AbbVie says stockholders should vote against its $55 billion takeover offer for Shire after tax changes reduced the financial advantages of the deal.
Want to invest in legalized marijuana but concerned about a DEA crackdown? What happens to wiretapping in Colorado may be an early clue of the feds' stance.
The party may soon be over for companies trying to dodge U.S. taxes through so-called inversions, a move that has become popular lately among drug firms.
They make for strange bedfellows, but Apple and IBM, which once competed in the personal computer era, are now teaming up in the digital age.
Stocks gain on Wall Street with broadcasting shares getting a big boost from the Supreme Court's decision against Aereo.
After a 40-year ban, a few companies have been given the green light to export unrefined oil, which could lead to higher gas prices in the U.S.